Key result
Han patients with cardiovascular and cerebrovascular diseases had a significantly higher frequency of CYP2C19 poor metabolizer genotypes compared to Uyghur patients (13.64% vs 4.76%, P<0.01).
Why the study?
Is there a difference in CYP2C19 genetic polymorphism frequencies between Han and Uyghur patients with cardiovascular and cerebrovascular diseases?
Cross-Sectional (n=1,020)
Is there a difference in CYP2C19 genetic polymorphism frequencies between Han and Uyghur patients with cardiovascular and cerebrovascular diseases?
Absolute Event Rate: 13.64% vs 4.76%
p-value: p=<0.01
There is a significant difference in CYP2C19 genotype distribution between Han and Uyghur patients, which may impact the efficacy of antiplatelet therapy like clopidogrel in these populations.
No takes yet. Share an insight, caveat, or question.
Ethnic CYP2C19 differences may influence drug response; leaves open need for outcome-validated, ethnicity-specific pharmacogenomics.
DU Xi-li (2014) conducted a cross-sectional in Cardiovascular and cerebrovascular diseases (n=1,020). Han ethnicity vs. Uyghur ethnicity was evaluated on Frequency of CYP2C19 poor metabolizer phenotype (p=<0.01). Han patients with cardiovascular and cerebrovascular diseases had a significantly higher frequency of CYP2C19 poor metabolizer genotypes compared to Uyghur patients (13.64% vs 4.76%, P<0.01).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: